Cite
MLA Citation
V Domenyuk et al.. “P-132Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets.” Annals of oncology, vol. 29, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100095506270.0x00002b